Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III
North America Head Brendan O’Grady Presses For Speedier Approvals
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.
